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Introduction
Angiotensin (Ang) II and other active peptides of the renin-
angiotensin system, such as Ang IV [Ang-(3-8)] and Ang-(1-
7), are mostly known as regulators in the cardiovascular sys-
tem.1 However, recent studies have shown that AngII and
Ang-(1-7) also have regulatory effect on tissue regeneration,
cellular proliferation and growth factor release.2,3 In vivo stud-
ies have shown that AngII and Ang-(1-7) increased
hematopoietic recovery after myelosuppression and progen-
itor engraftment.4,5 The increases in cell numbers were most
profound and long-lasting in the bone marrow, consistent
with the observed effects on early progenitors, and exhibit-
ed effects on multiple blood cell lineages. In addition to stim-
ulating bone marrow regeneration in vivo, AngII was also
shown to stimulate the proliferation of hematopoietic pro-
genitors in vitro in cells isolated from both mouse bone mar-
row and human cord blood.5,6 A recent publication showing
the presence of a key component of the renin-angiotensin
system, angiotensin converting enzyme, in the human
hemangioblast, supports the critical nature of this system in
hematopoietic development.7 In this report, we expand these
observations to show that Ang-(1-7) stimulates the prolifera-
tion and differentiation of CD34+ and mononuclear cells iso-
lated from human cord blood.8 Since it is not known how
these stimulatory effects of Ang-(1-7) relate to stimulation of
specific subspecies of mononuclear and progenitor cells in
vivo, we furthermore set out to study the in vivo effects of
Ang-(1-7) on human mononuclear cells monitored in
NOD/SCID mice.
Design and Methods
Effects of Ang-(1-7) on human mononuclear cells in vitro
Cord blood was obtained from the LAC Obstetrics Service
immediately after delivery by vacutainers containing 10 mM
of EDTA. The red blood cells were lysed, the nucleated cells
were pelleted and resuspended (107 cells/mL). To isolate
CD34+ cells, 10 µL of an antibody cocktail, containing anti-
bodies to glycophorin A, CD2, CD3, CD14, CD16, CD19,
CD24, CD56, and CD66b (CellSystems, St. Katharinen,
Germany), was added per ml of cells and cells were separat-
ed with magnetic beads (negative selection).8 After isolation,
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hematopoiesis and its promising therapeutic potential in
diseases requiring progenitor stimulation.
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the CD34+ cells were resuspended (5×104 cells/mL) in
serum free StemSpan (CellSystems, St. Katharinen,
Germany) containing the following human recombi-
nant factors: 3 IU/mL erythropoietin, 20 ng/mL stem
cell factor, 20 ng/mL interleukin 3 and 20 ng/mL gran-
ulocyte-macrophage colony-stimulating factor (GM-
CSF). The cells were cultured for six days (medium
change all 24 h) at 37°C in atmosphere of 5% CO2 in
air in the absence or presence of Ang-(1-7) as indicated
in Figure 1A and B. These cells were washed, counted,
resuspended (5×105 cells/mL) and cultured in individ-
ual cells of a 96-well microtiter plate (5×104 cells/well)
in semi-solid medium (0.9% methyl cellulose in
Iscove’s modified Dulbecco’s medium, 30% fetal calf
serum, 1% bovine serum albumin, 10 µM 2-mercap-
toethanol, 2 mM L-glutamine, 10% agar leukocyte
conditioned medium with and without 3 IU/mL ery-
thropoietin) without Ang-(1-7). At various time points
after initiation of culture, the number of large colonies
without evidence of erythroid differentiation as well
as the number of erythroid burst-forming units- (BFU-
E) per well were counted.
Effects of Ang-(1-7) on human mononuclear cells
in NOD/SCID mice
Human cord blood
Human cord blood cells were harvested at the time
of delivery at the Charité, Campus Benjamin Franklin,
Department of Obstetrics and HELIOS Klinikum
Berlin-Buch by gravity into tubes containing 5,000 IU
heparin. 
Mononuclear cells (MNC) were harvested from the
cord blood by density gradient centrifugation using
Lymphocytes separation medium (PAA Laboratories,
Cölbe, Germany). Cells were centrifuged at 400× g for
30 min at room temperature. The MNCs at the inter-
face were washed and resuspended (5×107 cells/mL).
Mice
NOD/LtSz-SCID/SCID mice were used in the exper-
iments. The animals were maintained under standard-
ized conditions with an artificial 12 h dark-light cycle,
with free access to food and water in the animal facil-
ity of the Max Delbrück Center (Berlin-Buch,
Germany). All animal studies were performed accord-
Figure 1. In vitro effect of Ang-(1-7) on cultured human cord blood derived CD34+ cells. The CD34+ cells were exposed to different con-
centrations of Ang-(1-7) in suspension culture, and then 5×104 cells/well were transferred to semi-solid medium. The number of large
colonies without evidence of erythroid differentiation (A) and BFU-E formed (B) where assessed at various times after initiation of cul-
ture in semi-solid medium. *p<0.05 vs. control [0 mg/mL Ang-(1-7)]. In vivo effect of Ang-(1-7) on bone marrow and spleen cells in
NOD/SCID mice. Representative flow cytometry density plots showing the effect of PBS and 10.8 µg Ang-(1-7)/mouse on isolated bone
marrow cells (C) and spleen cells (D). The percentage of cells positive for human HLA-I and CD19 is indicated in the top right corner of
each diagram. 
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ing to national guidelines and approved by the institu-
tional animal care committees. Mice were irradiated
sublethally at 6-8 weeks of age with a dose of 1.6 Gy
of a 137Cs-γ source before cell transplantation.
Treatment procedure
After isolation of human cord blood MNCs, 1×107
cells were injected intravenously into each mouse.
Starting two days after injection, the mice received
daily subcutaneous (s.c.) injections of PBS (Group A),
1.08 µg/d Ang-(1-7) (Group B) or 10.8 µg/d Ang-(1-7)
(Group C). At day 30, the mice were euthanized and
the spleen and bone marrow harvested to assess the
engraftment of human progenitors and mature cells by
flow cytometry. The average amount of harvested
MNCs was 2×107 from bone marrow and 1.5×108 from
spleen without differences between the treatment
groups.
Flow cytometry
Two-color immunofluorescence cytometry was used
to quantify the expression of cell surface molecules on
suspended bone marrow and spleen cells. Cell viability
was tested by staining with trypanblue. The cells were
stained with phycoerythrin (PE) or fluorescein isothio-
cyanate (FITC) labeled monoclonal antibodies against
human anti-CD34 (clone 581), anti-CD11a (clone G43-
25B), anti-CD19 (clone HI B19), anti-CD 15 (clone H
198), anti-HLA-DR (clone G46-6), anti-HLA-I (clone
G46-2.6) from Becton Dickinson (Becton Dickinson,
Heidelberg, Germany). FITC and PE conjugated iso-
type-matched mouse IgGs (clone X40) from Becton
Dickinson were used to determine background stain-
ing. After 25 min of incubation in the dark, cells were
washed in PBS and analyzed immediately in a dual-
laser FACSCalibur (Becton Dickinson) flow cytometer
with Cell-Quest-Software. Each measurement con-
tained 10,000 events and cell debris was excluded by
threshold. 
Statistical analysis 
Data was expressed by mean±SEM. Statistical analy-
sis was performed by the Student’s t test. Statistical sig-
nificance was assumed when p≥0.05. 
Results and Discussion
In vitro Ang-(1-7) effects on human 
mononuclear cells
CD34+ cells isolated from human cord blood were
expanded in vitro in the presence of Ang-(1-7). After the
expansion phase, the cells were transferred to semi-solid
medium for assessment of colony formation. This
experiment showed that in vitro Ang-(1-7) increased the
number of large (> 50 cells per colony) colonies without
evidence of erythroid differentiation (Figure 1A) and
BFU-E (Figure 1B) in a dose-dependent manner.
In vivo Ang-(1-7) effects on human 
mononuclear cells in mice
To investigate whether these effects of Ang-(1-7)
could also be observed under in vivo conditions and to
identify the cell populations that are stimulated, a
study was designed to evaluate human cord blood pro-
genitor engraftment into NOD/SCID mice after appli-
cation of two different concentrations of Ang-(1-7) by
daily s.c. injection. Administration of PBS alone result-
ed in approximately 0.5% of the bone marrow cells
(Figure 1C and Table 1) and 0.3% of the splenocytes
(Figure 1D and Table 1) being of human origin.
Administration of the lower dose of Ang-(1-7) did not
have significant impact on the stimulation and recruit-
ment of human cells in bone marrow and spleen,
respectively, whereas administration of the high dose
of peptide increased the number of human cells (HLA-
I+ cells) in the bone marrow approximately 42-fold
(Figure 1C and Table 1) and in the spleen approximate-
ly 7-fold (Figure 1D and Table 1). CD34+ cells were also
identified in the bone marrow and spleen of placebo-
treated mice. Both doses of Ang-(1-7) increased CD34+
cells in the bone marrow in a dose-dependent manner
(20- and 600-fold for low and high dose, respectively)
(Table 1). At the high dose of Ang-(1-7), the percentage
of splenocytes that expressed human CD34 was
increased 6-fold over placebo (Table 1). Differentiated
cells of human origin [myelomonocytic (CD15, CD11a,
HLA DR) and B cell (CD19, HLA DR) lineage] were
found at very low levels in the bone marrow (0.19-
0.41%) and spleen (0-0.11%) of vehicle-treated mice
(Figure 1C and D, and Table 1). While administration of
low-dose Ang-(1-7) did not affect the number of differ-
entiated cells of the hematopoietic human lineage,
administration of the higher dose of the heptapeptide
highly significantly increased the number of CD19+,
CD15+, CD11a+, and HLA DR+ cells in the bone mar-
row and spleen of treated animals at day 30 (Figure 1C
and D, and Table 1).
Ang-(1-7) has been described as having a growing
Table 1. Percentage of human cells and subpopulations in bone mar-
row and spleen of NOD/SCID mice, treated for 30 days post injec-
tion of mononuclear cells with A: daily injection of PBS s.c.; B: daily
injection of 1.08 µg/mouse Ang-(1-7) s.c.; C: daily injection of 10.8
µg/mouse Ang-(1-7) s.c. 1p≤0.05, 2p≤0.01, 3p≤0.001 vs. A
(Student’s t test).
Organ Marker A B C
Bone marrow
HLA-I 0.5±0.2 0.7±0.3 21.2±43
CD34 0.01±0.01 0.2±0.11 6.2±1.53
CD19 0.2±0.03 0.27±0.1 9.2±2.13
CD15 0 0.13±0.1 0.1±0.1
CD11a 0.19±0.09 0.08±0.04 8.4±2.23
HLA-DR 0.41±0.17 1.0±0.4 15.9±3.13
Spleen
HLA-I 0.3±0.1 0.14±0.3 2.1±0.33
CD34 0.04±0.02 0.01±0.1 0.24±0.052
CD19 0.09±0.03 0.01±0.1 1.27±0.152
CD15 0 0 0.01±0.01
CD11a 0.01±0.01 0 0.21±0.032
HLA-DR 0.11±0.03 0.41±0.26 1.09±0.093
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number of beneficial effects in cardiovascular diseases.
Our data points to the conclusion that a broad spec-
trum of such beneficial activities observed with Ang-
(1-7) may be due to actions on early progenitor cells.
Most of the Ang-(1-7) effects are NO-mediated. NO
has been shown to have regulatory effects on e.g.
endothelial progenitors,9 and first data indicates a
potential role in the proliferation and mobilization of
hematopoietic stem cells.10 Thus, further sets of exper-
iments have to clarify whether the here newly identi-
fied effects of Ang-(1-7) are also NO-mediated.
Since stem cells derived from adults may be highly
versatile or plastic, transplantation of bone marrow or
activation of endogenous bone marrow cells could
result in donor/activated cells possessing the added
benefit of mediating the healing of injuries to the CNS,
muscle, liver, and heart. Therefore, an agent that stim-
ulates the proliferation and differentiation of stem cells
has the potential for similar versatility. Given our pres-
ent results, defining Ang-(1-7)’s versatility with respect
to hematopoietic progenitor cell stimulation, it seems
worthwhile to explore this heptapeptide as a regener-
ative agent beyond the scope of bone marrow repopu-
lation and cardiovascular repair.
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